Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 14/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 15/20 | 0.41 |
| ▸ | USP2 | O75604 | 9/20 | 0.41 |
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24926327 | 0.92 | CYP3A4 (0.50) | CYP2D6CYP3A4USP2TSHRCYP2C19 | |
| SCHEMBL21934376 | 0.89 | CYP2D6 (0.47) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL24411695 | 0.89 | CYP2D6 (0.54) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL18926698 | 0.85 | CYP2D6 (0.56) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL18212474 | 0.85 | CYP2D6 (0.52) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL13400658 | 0.81 | CYP3A4 (0.51) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL24751941 | 0.81 | CYP3A4 (0.51) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL17285924 | 0.79 | CYP2D6 (0.47) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR | |
| SCHEMBL22200114 | 0.79 | TSHR (0.49) | TSHR | |
| SCHEMBL19969931 | 0.79 | CYP3A4 (0.50) | CYP2D6SMN1; SMN2CYP3A4USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322661-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-10-24 | — | — | US | disclosed |
| US-20170145020-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145020-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9604984-B2 | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160237086-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-9346815-B2 | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150336962-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322661-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | CYP2D6 202/4885SMN1; SMN2 3594/4885CYP3A4 229/4885 |
| US-20150336962-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | CYP2D6 202/4885SMN1; SMN2 3594/4885CYP3A4 229/4885 |
| US-20160237086-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | CYP2D6 202/4885SMN1; SMN2 3594/4885CYP3A4 229/4885 |
| US-20170145020-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | CYP2D6 202/4885SMN1; SMN2 3594/4885CYP3A4 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.